FDA moves on peptides put consumers in harm's way

The FDA is considering allowing several unproven peptides to be compounded and sold by pharmacists, raising concerns about consumer safety, regulatory integrity, and potential undermining of the drug approval process. Conflicts of interest in advisory committee appointments and political pressure threaten the agency's standards and may open the market to unsafe, poorly regulated peptide products.

This Wire brief sits within Fusion42's coverage of Health.